Form 4: IGM Biosciences Director Acquires Stock Options
SEC Form 4 Filing
Christina Teng Topsoe, a director at IGM Biosciences, acquired stock options for 29,400 shares on March 12, 2024.
Summary
- On March 12, 2024, Christina Teng Topsoe, a director of IGM Biosciences, acquired stock options for 29,400 shares of common stock.
- The exercise price of these options is $9.95 per share.
- The options vest monthly, with 1/12 of the shares vesting each month following the Issuer's 2024 Annual Meeting of Stockholders, contingent on continued service.
- Full vesting will occur no later than the date of the Issuer's 2025 Annual Meeting of Stockholders.
- The options expire on March 12, 2034.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock option grants, and does not contain information that would significantly impact sentiment.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
This is a standard Form 4 filing, reflecting a director's acquisition of stock options, which is a common practice in publicly traded companies to align management's interests with those of shareholders.
Stakeholder Impact
- The acquisition of stock options by a director can align their interests with those of shareholders, potentially incentivizing them to work towards increasing shareholder value.
Key Dates
| Date | Description |
|---|---|
| 03/12/2024 | Date of transaction: Director acquired stock options for 29,400 shares at $9.95. |
| 03/14/2024 | Date of filing: Form 4 filing date. |
| 03/12/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.